EFFECTS OF CARDICHOL, AN HERBAL DIETARY SUPPLEMENT, IN MODERATE HYPERCHOLESTEROLEMIA

NCT02657759 | Unknown

• 1 other identifier: DPlantes
• Study Type: interventional
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

This research aims to evaluate the effect of CARDICHOL chronic consumption (12 weeks) on lipid metabolism and especially on blood LDL cholesterol in volunteers with moderate hypercholesterolemia.

Conditions

HYPERCHOLESTEROLEMIA

Outcome Measures

Primary Outcomes (1)

• Change of the fasting blood LDL cholesterol NCEP concentration

  8 weeks

Secondary Outcomes (23)

• Change of the fasting blood LDL cholesterol concentration (NCEP and Friedewald estimation methods)

  4 weeks

• Change of the fasting blood LDL cholesterol concentration (Friedewald estimation method)

  8 weeks

• Change of the fasting blood LDL cholesterol concentration (NCEP and Friedewald estimation methods)

  12 weeks

• Change of the fasting blood HDL cholesterol concentration (NCEP and direct methods)

  4 weeks

• Change of the fasting blood HDL cholesterol concentration (NCEP and direct methods)

  8 weeks

Other Outcomes (23)

• Complete blood count

  12 weeks

• Blood Aspartate Amino Transferase

  12 weeks

• Blood Alanine Amino Transferase

  12 weeks

Study Arms (2)

CARDICHOL

EXPERIMENTAL

Food supplement formula in shape of pill called CARDICHOL. 2 pills daily during 12 weeks (from visit V1 to visit V4). One pill immediately before, after or during breakfast and lunch.

Dietary Supplement: CARDICHOL

Placebo

PLACEBO COMPARATOR

placebo with the same characteristics, appearance, packaging, and composition as the active formula, except for active ingredients replaced by dicalcium phosphate and flavouring substances. 2 pills daily during 12 weeks (from visit V1 to visit V4). One pill immediately before, after or during breakfast and lunch.

Dietary Supplement: PLACEBO

Interventions

CARDICHOL DIETARY_SUPPLEMENT

CARDICHOL

PLACEBO DIETARY_SUPPLEMENT

Placebo

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• To be eligible to the study, male and female volunteers will have to fulfill the following criteria (assessment based on the medical examination performed at V0 with a checking at V1):
• Age between 18 and 65 years (limits included).
• BMI between 18,5 and 30 kg/m² (limits excluded).
• For women: Non menopausal with the same reliable contraception since at least three cycles before the beginning of the study and agreeing to keep it during the entire duration of the study (condom alone without spermicide gel excluded) or menopausal without or with hormone replacement therapy (oestrogenic replacement therapy begun from less than 3 month excluded).
• Good general and mental health with in the opinion of the investigator: no clinically significant and relevant abnormalities of medical history or physical examination.
• Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form.
• Affiliated with a social security scheme.
• Agree to be registered on the volunteers in biomedical research file.
• After V0 biological analysis the subjects will be eligible to the study on the following criteria:
• \- Fasting blood LDLc level (Friedewald estimation method) between 1,3 and 2,2g/L (limits included with ± 2% tolerated around).
• A re-screening can occur from 2 months after the exit of study for failure to comply with the one or more of the eligibility criteria listed above.

You may not qualify if:

• Volunteers with the following criteria will be considered as non eligible to the study (assessment based on the medical examination performed at V0 with a checking at V1):
• Suffering from a metabolic disorder such as diabetes, uncontrolled thyroidal trouble or other metabolic disorder.
• Suffering from a severe chronic disease (e.g. cancer, HIV, renal failure, hepatic or biliary disorders ongoing, chronic inflammatory digestive disease, arthritis or other chronic respiratory trouble, etc.) or gastrointestinal disorders found to be inconsistent with the conduct of the study by the investigator (e.g. celiac disease).
• With a history of ischemic cardiovascular event or, during the previous 6 months a surgical procedure.
• Suffering from an uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg).
• With a known or suspected food allergy or intolerance or hypersensitivity to any of the study products' ingredient.
• Pregnant or lactating women or intending to become pregnant within 4 months ahead.
• Requiring a cholesterol lowering by immediate pharmacologic intervention according to the current recommendations (AFSSAPS 2005).
• Under lipid-lowering treatment (e.g. statins, fibrates, ezetimibe, bile acid sequestrants, niacin, etc.) or stopped less than 4 months before the randomization.
• Under medication which could affect blood lipid parameters (e.g. long-term corticosteroid systemic drug, systemic antibodies, androgens or phenytoin, etc.) or stopped less than 1 month before the randomization (stable long-term treatment with beta blocker or thiazide diuretics tolerated).
• Regular intake of dietary supplements or "health foods" which are known to decrease LDLc or triglycerides (e.g. rich in plant stanol or sterol like PRO-ACTIV or DANACOL products, red yeast rice, policosanol, capsules containing omega-3 fatty acids from fish oils, etc.) or stopped less than 3 months before the randomization.
• Under treatment or dietary supplement which could significantly affect parameter(s) followed during the study according to the investigator or stopped in a too short period before the randomization.
• With significant change in food habits or in physical activity in the 3 months before randomization or not agreeing to keep them unchanged throughout the study.
• With reported body weight variation \> 5% in the 3 months prior the randomization or with a hyper or hypocaloric diet planned in the next 4 months.
• With a personal history of anorexia nervosa, bulimia or significant eating disorders according to the investigator.

Sponsors & Collaborators

• Direct Plantes: lead

Study Sites (1)

Biofortis

Saint-Herblain, 44800, France

RECRUITING

MeSH Terms

Conditions

Hypercholesterolemia

Condition Hierarchy (Ancestors)

Hyperlipidemias; Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Officials

• Patrice CHAUVEAU

  BioFortis

  STUDY DIRECTOR

Central Study Contacts

Patrice CHAUVEAU

CONTACT

+ 33 (0)2 40 20 45 65; patrice.chauveau@mxns.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 14, 2016
• First Posted: January 18, 2016
• Study Start: December 1, 2015
• Primary Completion: May 1, 2016
• Study Completion: May 1, 2016
• Last Updated: January 20, 2016

Record last verified: 2016-01

Locations

FR (1)